Abstract
Recently, nasal administration has been studied as a noninvasive route for delivery of plasmid DNA encoding therapeutic or antigenic genes. Here, we examined the brain targeting efficiency and transport pathways of intranasally administered plasmid DNA. Quantitative polymerase chain reaction (PCR) measurements of plasmid DNA in blood and brain tissues revealed that intranasally administered pCMVβ (7.2 kb) and pN2/CMVβ (14.1 kb) showed systemic absorption and brain distribution. Following intranasal administration, the β-galactosidase protein encoded by these plasmids was significantly expressed in brain tissues. Kinetic studies showed that intranasally administered plasmid DNA reached the brain with a 2,595-fold higher efficiency than intravenously administered plasmid DNA did, 10 min post-dose. Over 1 h post-dose, the brain targeting efficiencies were consistently higher for intranasally administered plasmid DNA than for intravenously administered DNA. To examine how plasmid DNA enters the brain and moves to the various regions, we examined tissues from nine brain regions, at 5 and 10 min after intranasal or intravenous administration of plasmid DNA. Intravenously administered plasmid DNA displayed similar levels of plasmid DNA in the nine different regions, whereas, intranasally administered plasmid DNA exhibited different levels of distribution among the regions, with the highest plasmid DNA levels in the olfactory bulb. Moreover, plasmid DNA was mainly detected in the endothelial cells, but not in glial cells. Our results suggest that intranasally applied plasmid DNA may reach the brain through a direct route, possibly via the olfactory bulb, and that the nasal route might be an alternative method for efficiently delivering plasmid DNA to the brain.
Similar content being viewed by others
References
Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES (2002) Eradication of osteosarcoma lung metastases following intranasal interleukin-12P gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 9:260–266
Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W (2000) Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 192:41–52
Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR (2000) Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7:1156–1165
Minn A, Leclerc S, Heydel JM, Minn AL, Denizcot C, Cattarelli M, Netter P, Gradinaru D (2002) Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier. J Drug Target 10:285–296
Fisher RS, Ho J (2002) Potential new methods for antiepileptic drug delivery. CNS Drugs 16:579–593
Thorne RG, Frey WH (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40:907–946
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514–516
De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 102:3811–3816
Oh YK, Kim JP, Hwang TS, Ko JJ, Kim JM, Yang JS, Kim CK (2001) Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 19: 4519–4525
Chun S, Daheshia M, Lee S, Eo SK, Rouse BT (1999) Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10. J Immunol 163:2393–2402
Oh YK, Suh D, Kim JM, Choi HG, Shin K, Ko JJ (2002) Polyethylenimine-mediated cellular uptake, nucleus trafficking and expression of cytokine plasmid DNA. Gene Ther 9:1627–1632
Zerbini M, Gallinella G, Manaresi E, Musiani M, Gentilomi G, Venturoli S (1999) Standardization of a PCR-ELISA in serum samples: diagnosis of active parvovirus B19 infection. J Med Virol 59:239–244
Kang MJ, Kim CK, Kim MY, Hwang TS, Kang SY, Kim WK, Ko JJ, Oh YK (2004) Skin permeation, biodistribution, and expression of topically applied plasmid DNA. J Gene Med 6:1238–1246
Ichikawa N, Naora K, Hirano H, Hashimoto M, Masumura S, Iwamoto K (1996) Isolation and primary culture of rat cerebral microvascular endothelial cells for studying drug transport in vitro. J Pharmacol Toxicol Methods 36:45–52
Stein VM, Czub M, Hansen R, Leibold W, Moore PF, Zurbriggen A, Tipold A (2004) Characterization of canine microglial cells isolated ex vivo. Vet Immunol Immunopathol 99:73–85
Oh YK, Kim JP, Yoon H, Kim JM, Yang JS, Kim CK (2001) Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther 8:1587–1592
Roon KI, Soons PA, Uitendaal MP, de Beukelaar F, Ferrari MD (1999) Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. Br J Clin Pharmacol 47:285–290
Nishikawa M, Takemura S, Kadakura Y, Hashida M (1998) Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(l-lysine) complexes by controlling their physicochemical properties. J Pharm Exp Ther 287:408–415
Graff CL, Pollack GM (2005) Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 94:1187–1195
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481–496
Provost N, Le Meur G, Weber M, Mendes-Madeira A, Podevin G, Cherel Y, Colle MA, Deschamps JY, Moullier P, Rolling F (2005) Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther 11:275–283
Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551–555
Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Bjorklund A, Kirik D (2005) Reversal of dyskinesias in an animal model of Parkinson’s disease by continuous l-DOPA delivery using rAAV vectors. Brain 128:559–569
Tanaka SI, Yamakawa T, Kimura M, Aoki I, Kamei J, Okuda K, Mobbs C (2004) Daily nasal inoculation with the insulin gene ameliorates diabetes in mice. Diabetes Res Clin Pract 63:1–9
Devito C, Zuber B, Schroder U, Benthin R, Okuda K, Broliden K, Wahren B, Hinkula J (2004) Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173:7078–7089
Hino T, Yokota T, Ito S, Nishina K, Kang YS, Mori S, Hori S, Kanda T, Terasaki T, Mizusawa H (2006) In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem Biophys Res Commun 340:263–267
Djupesland PG, Skretting A, Winderen M, Holand T (2004) Bi-directional nasal delivery of aerosols can prevent lung deposition. J Aerosol Med 17:249–259
Newman SP, Pitcairn GR, Dalby RN (2004) Drug delivery to the nasal cavity: in vitro and in vivo assessment. Crit Rev Ther Drug Carr Syst 21:21–66
Acknowledgments
This research was financially supported by grants from Ministry of Science and Technology (F104AA010002-06A0101-00210), and from the Korea Science and Engineering Foundation (KOSEF R01-2005-000-10292-0).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Han, IK., Kim, M.Y., Byun, HM. et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med 85, 75–83 (2007). https://doi.org/10.1007/s00109-006-0114-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-006-0114-9